Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration

Archives of Ophthalmology

Volumn 123, Issue 7, 2005, Pages 957-963

  Lim, Wee Kiak ^a,b   Fujimoto, Chiaki ^a   Ursea, Roxana ^a   Mahesh, Sankaranarayana Pillai ^a   Silver, Phyllis ^a   Chan, Chi Chao ^a   Gery, Igal ^a   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CYTOKINE; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; PHOSPHATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; EYE PROTEIN; HEN EGG LYSOZYME; IL1RN PROTEIN, HUMAN; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LYSOZYME; RECOMBINANT PROTEIN; RETINOL BINDING PROTEIN; RETINOL-BINDING GLYCOPROTEIN; SIALOGLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HEN; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; UVEITIS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TH1 CELL;

ADOPTIVE TRANSFER; ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; EYE PROTEINS; FEMALE; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MURAMIDASE; RECOMBINANT PROTEINS; RETINOL-BINDING PROTEINS; SIALOGLYCOPROTEINS; TH1 CELLS; UVEITIS;

EID: 22844449524     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.7.957     Document Type: Article

References (28)

1. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303-308.
2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
3. de Smet MD, Chan CC. Regulation of ocular inflammation-what experimental and human studies have taught us. Prog Retin Eye Res. 2001;20:761-797.
4. Mochizuki M, Nussenblatt RB, Kuwabara T, Gery I. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci. 1985;26:226-232.
5. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106-113.
6. Foxman EF, Zhang M, Hurst SD, et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 2002;168:2483-2492.
7. El-Shabrawi YG, Christen WG, Foster SC. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res. 2000;20:211-214.
8. Wawrousek EF, Lai JC, Gery I, Chan CC. Progressive inflammatory disease and neovascularization in the eyes of interleukin-1 beta transgenic mice. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I, eds. Advances in Ocular Immunology. Amsterdam, the Netherlands: Elsevier; 1994:143-146.
9. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A. 1991;88:5232-5236.
10. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991;266:10331-10336.
11. Cominelli F, Bortolami M, Pizarro TT, et al. Rabbit interleukin-1 receptor antagonist: cloning, expression, functional characterization, and regulation during intestinal inflammation. J Biol Chem. 1994;269:6962-6971.
12. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today. 1991;12:404-410.
13. Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol. 1995;61:241-245.
14. Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol. 2002;20:S32-S34.
15. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927-934.
16. Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res. 2003;76:161-167.
17. Yamada J, Dana MR, Zhu SN, Alard P, Streilein JW. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Arch Ophthalmol. 1998;116:1351-1357.
18. Kim SJ, Zhang M, Vistica BP, et al. Induction of ocular inflammation by T-helper lymphocytes type 2. Invest Ophthalmol Vis Sci. 2002;43:758-765.
19. Pepperberg DR, Okajima TL, Ripps H, Chader GJ, Wiggert B. Functional properties of interphotoreceptor retinoid-binding protein. Photochem Photobiol. 1991;54:1057-1060.
20. Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140:1490-1495.
21. Caspi RR, Chan CC, Wiggert B, Chader GJ. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr Eye Res. 1990;9(suppl):169- 174.
22. Chan CC, Caspi RR, Ni M, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun. 1990;3:247-255.
23. Moody MD, Van Arsdell SW, Murphy KP, Orencole SF, Burns C. Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques. 2001;31:186-190, 192-194.
24. Redmond TM, Sanui H, Hu LH, et al. Immune responses to peptides derived from the retinal protein IRBP: immunopathogenic determinants are not necessarily immunodominant. Clin Immunol Immunopathol. 1989;53:212-224.
25. Snedecor GW, Cochran WG. Research Methodology Statistical Methods. 6th ed. Ames: Iowa State University Press; 1967.
26. Rosenbaum JT, Boney RS. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol. 1992;110:547-549.
27. Wiemann B, Van GY, Danilenko DM, et al. Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist. Exp Neurol. 1998;149:455-463.
28. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25:1115-1124.